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In Egypt, breast cancer is the most common cancer among women.1 Many patients with relapsed met-astatic breast cancer are pre-treated with taxanes 
and anthracyclines, which are usually given in the neo-
adjuvant/adjuvant setting or as first-line treatment for 
metastatic disease. These women require effective and 
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BACKGROUND AND OBJECTIVES: many patients with relapsed metastatic breast cancer are pre-treated with 
taxanes and anthracyclines, which are usually given in the neoadjuvant/adjuvant setting or as first-line treat-
ment for metastatic disease. the primary objective of this study was to determine the overall response rate for 
combination treatment with gemcitabine and cisplatin in patients with locally advanced or metastatic breast 
cancer who had relapsed after receiving one adjuvant/neoadjuvant or first-line metastatic chemotherapy regi-
men containing an anthracycline with/without a taxane. secondary endpoints included duration of response, 
time to progression, one-year survival probability, and toxicity.
DESIGN AND SETTING: a single-arm, open-label, phase 2 study conducted at 17 investigative sites in Egypt.
PATIENTS AND METHODS: treatment consisted of gemcitabine (1250 mg/m2) on Days 1 and 8 and cisplatin 
(70 mg/m2) on Day 1 of each 21-day cycle. treatment continued until disease progression or a maximum of 6 
cycles. 
RESULTS: of 144 patients all were evaluable for safety and 132 patients were evaluable for efficacy. the overall 
response rate was 33.3% and 45.5% of the patients with stable disease as their best response. the median time 
to progression was 5.1 months and the one-year survival probability was 73%. the most common grade 3/4 ad-
verse events were nausea/vomiting (20.1%), neutropenia (19.4%), anemia (13.9%), asthenia (11.1%), diarrhea 
(9.7%), stomatitis (7.6%), leucopenia (7.6%), and thrombocytopenia (6.2%). twelve (8.3%) patients had serious 
adverse events. 
CONCLUSIONS: the results of this study indicate that gemcitabine and cisplatin were active and generally well 
tolerated in pretreated patients with locally advanced or metastatic breast cancer.
well-tolerated treatment options, particularly after early 
relapse following adjuvant taxane-based treatment. 
Gemcitabine has previously been studied in phase 
1 and 2 clinical trials as monotherapy or combina-
tion therapy for advanced or metastatic breast cancer. 
Response rates of 12% to 46% have been observed 
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when gemcitabine was given as a single agent to pre-
viously treated or untreated patients with advanced or 
metastatic breast cancer.2-10 Response rates of 26% to 
50% have been observed for gemcitabine in combina-
tion with cisplatin in heavily pretreated patients with 
metastatic breast cancer.11-13
We conducted a phase 2 study to examine the ef-
ficacy and safety of combination therapy with gem-
citabine and cisplatin in patients with locally advanced 
or metastatic breast cancer who had relapsed after re-
ceiving one prior chemotherapy regimen containing an 
anthracycline (with or without a taxane) as adjuvant or 
neoadjuvant therapy or as first-line therapy for meta-
static disease. 
METHODS
This single-arm, non-randomized, open-label phase 2 
study was conducted at 17 investigative sites in Egypt. 
The first patient was enrolled in July 2002 and the last 
patient visit was in March 2005. The study was con-
ducted in accordance with the Declaration of Helsinki 
and Good Clinical Practice guidelines, and was ap-
proved by the ethics review board at each investigative 
site. All patients provided written informed consent be-
fore participating in the study.
Female patients, aged 18 to 75 years, with a histo-
logical or cytological diagnosis of breast cancer with 
evidence of unresectable, locally recurrent or metastatic 
disease (not amenable to surgery or radiation treatment 
of curative intent) were eligible for this study. Other in-
clusion criteria included a Karnofsky performance sta-
tus of >70%; prior treatment with one anthracycline-
containing chemotherapy regimen (with or without 
taxanes) in the neoadjuvant/adjuvant setting or as first-
line treatment for metastatic disease with subsequent 
documented disease progression, a bidimensionally 
measurable lesion with clearly defined margins on x-ray, 
computed tomography (CT) scan, or physical exami-
nation, an estimated life expectancy of ≥6 months and 
adequate bone marrow reserve, liver and renal function. 
Previous hormonal therapy in the adjuvant setting or 
for local recurrence of metastatic disease was allowed 
and previous therapy with humanized anti-HER2 an-
tibody was permitted. Prior radiation therapy was per-
mitted if the irradiated area was not the only source of 
measurable disease and there was ≥2 weeks between the 
end of radiotherapy and study entry. Exclusion criteria 
included known brain metastasis, serious concomitant 
systemic disorders, bone metastasis, pleural effusion, or 
ascites as the only site of disease, and radiation of >20% 
of the total bone marrow producing areas.
Gemcitabine (1250 mg/m2) was given intravenously 
over approximately 30 minutes on Days 1 and 8 of each 
21-day cycle. Cisplatin (70 mg/m2) was given intrave-
nously over approximately 3 hours on Day 1 of each 21-
day cycle. Cisplatin was given according to institutional 
guidelines with appropriate pre- and post-infusion hy-
dration. Study treatment was intended to continue for 
a maximum of 6 cycles, but was discontinued prema-
turely in the event of disease progression, unacceptable 
toxicity, or the patient or physician requested discon-
tinuation. 
Study treatment could be delayed for up to 4 weeks 
to allow patients time to recover from treatment-related 
toxicity. Patients were discontinued if a cycle was de-
layed for >4 weeks due to toxicity. Study drug doses 
were reduced by one level at the start of a cycle (a maxi-
mum of two dose level reductions were allowed) in the 
event of an absolute neutrophil count (ANC) <0.5× 
109/L for >5 days or <0.1×109/L for >3 days; febrile 
neutropenia; platelets <25×109/L for ≥3 days; a cycle 
delay of >1 week due to toxicity; or grade 3 non-hema-
tologic toxicity (except nausea, vomiting, or alopecia). 
Dose level -1 was 1000 mg/m2 gemcitabine on Days 
1 and 8 and 50 mg/m2 cisplatin on Day 1. Dose level 
-2 was 800 mg/m2 gemcitabine on Days 1 and 8 and 
cisplatin was omitted. Study treatment was withheld in 
the event of grade 4 non-hematologic toxicity.
The following dose adjustments were required 
within a cycle. The gemcitabine dose on Day 8 was 
reduced to 1000 mg/m2 if the patient’s ANC was be-
tween 1 to ≤1.5×109/L and/or the thrombocyte count 
was between 75 to 99×109/L. The gemcitabine dose on 
Day 8 was omitted if neutrophil and/or thrombocyte 
counts were <1×109/L and <75×109/L, respectively. 
Gemcitabine was discontinued in the event of ≥grade 
3 pulmonary toxicity. In the event of grade 3 non-he-
matologic toxicity (other than nausea, vomiting, or alo-
pecia), the gemcitabine dose on Day 8 was reduced to 
1000 mg/m2 or withheld. Gemcitabine was omitted on 
Day 8 in the event of grade 4 non-hematologic toxic-
ity (except alopecia). Cisplatin was reduced to 80% or 
withheld, at the discretion of the investigator, due to 
tinnitus or clinically significant hearing loss.
Full supportive care therapies were permitted during 
the study except for the prophylactic use of growth fac-
tors. Concomitant therapy with any other anti-cancer 
therapy or experimental treatment was not allowed. 
Palliative radiation was permitted for painful metas-
tases if indicator lesions were not irradiated, a limited 
target volume was used, and it did not interfere with 
study therapy continuation.
The clinical investigators performed all of the as-
sessments. Screening assessments occurred within 1 to 
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2 weeks before study therapy initiation and included 
a medical history, physical examination, tumor assess-
ment, and electrocardiogram and assessment of con-
comitant medications, vital signs, performance status 
(PS), and the collection of blood samples. At the be-
ginning of each cycle, weight, PS, concomitant medica-
tions, pre-existing conditions, and adverse events were 
assessed and a limited physical exam was performed. 
Blood samples for standard laboratory tests were col-
lected within 48 hours of the start of chemotherapy on 
Days 1 and 8 of each cycle.
Tumor assessments were completed within 2 weeks 
before study therapy initiation and approximately ev-
ery 6 weeks during study therapy. Tumor responses 
were categorized according to the World Health 
Organization’s (WHO) response criteria.14 After 
study treatment discontinuation, follow-up visits were 
scheduled every 3 months and included the assess-
ment of additional anti-cancer treatment, tumor assess-
ment (for patients without documented progression), 
and survival. Adverse events were monitored up until 
30 days after the last dose of study drug, after which 
only serious, study drug-related adverse events were re-
ported. Toxicity was graded according to the WHO’s 
recommendations14 except for neurotoxicity, which was 
graded according to the National Cancer Institute’s 
Common Toxicity Criteria (NCI CTC).
The primary objective of this phase 2 study was to 
determine the overall response rate for combination 
therapy with gemcitabine and cisplatin in patients 
with locally advanced or metastatic breast cancer who 
had relapsed after receiving one prior chemotherapy 
regimen containing an anthracycline (with or without 
a taxane) as adjuvant or neoadjuvant therapy or as first-
line therapy for metastatic disease. The secondary ob-
jectives of this study were to determine the duration of 
response, time-to- disease progression (TTP), 1-year 
survival, overall survival (OS), and to characterize the 
nature of toxicity. 
The primary outcome measure was the overall tu-
mor response rate, which was calculated by dividing 
the number of patients with a best clinical response of 
a complete response (CR) or a partial response (PR) by 
the number of patients in the tumor analysis popula-
tion and multiplying by 100. The enrollment target for 
this study was 150 patients, which was estimated to al-
low an accurate determination of a tumor response rate 
of 50% with a 95% confidence interval (CI) of 42% to 
58%. Secondary efficacy endpoints were Kaplan-Meier 
analyses for the duration of response, TTP, one-year 
survival, and OS. Duration of response was calculated 
from the date of the first documentation of a CR or PR 
until the date of disease progression or death due to any 
cause, and was censored at the date of the last tumor 
assessment for patients who had not died and did not 
have disease progression. TTP was calculated from the 
date of randomization to the date of documented pro-
gression, and was censored at the date of the last tumor 
assessment for patients without documented progres-
sion or the date of death for patients who died before 
disease progression. OS was calculated from the date of 
randomization to the date of death, and was censored at 
the last contact date for patients who were still alive at 
the end of the study. 
All enrolled patients were included in the tumor re-
sponse analysis if they had received prior chemotherapy 
with an anthracycline-based regimen (with or without 
a taxane) and no more than one previous chemotherapy 
regimen for metastatic disease, had not received any ex-
cluded concomitant therapy, and had bidimensionally 
measurable disease. Responding patients in the tumor 
analysis population were included in the analysis of 
duration of response. All other secondary efficacy mea-
sures were analyzed using all the enrolled patients, and 
the safety measures were analyzed using all of the en-
rolled patients who received ≥1 dose of study therapy.
Statistical analyses were performed by statisticians 
at Eli Lilly and Company (the sponsor of this study) 
using SAS® software, versions 8 and 9 (SAS Institute 
Inc., Cary, NC, USA).
RESULTS
A total of 144 patients were enrolled and received at 
least one dose of study therapy. All 144 patients were 
included in the safety analysis population and 132 
(91.7%) patients with evaluable tumor responses were 
included in the efficacy analysis population. A total of 
56 (38.9%) patients completed study treatment and 
88 (61.1%) patients discontinued early, predominantly 
due to PD (n=55; 38.2%), but also because of patient 
(n=14; 9.7%), or physician decision (n=7; 4.9%).
Table 1 summarizes baseline characteristics of the pa-
tients. The median age was 47.5 years and 68.1% of the pa-
tients were postmenopausal. Most (91.0%) patients had a 
pathological diagnosis of ductal breast carcinoma and met-
astatic disease (99.3%) at study entry. Most patients had 
received prior surgery (91.7%) and/or prior adjuvant che-
motherapy (83.3%). Less than half of the patients (41.7%) 
had received prior chemotherapy for locally advanced or 
metastatic disease. A total of 108 (75.0%) patients had re-
ceived prior anthracycline treatment in the adjuvant setting 
and 42 (29.2%) patients had received prior anthracycline 
treatment for locally advanced or metastatic disease.
All 144 patients received at least one dose of study 
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therapy (cisplatin and gemcitabine on Day 1 of Cycle 
1) and 527 complete cycles of study therapy were ad-
ministered. A total of 88 patients received both study 
drugs on Day 1 of Cycle 4 (76 of these patients also 
received the Day 8 dose of gemcitabine in Cycle 4), and 
63 patients received both study drugs on Day 1 of Cycle 
6, of whom 59 patients also received the Day 8 dose of 
gemcitabine in Cycle 6. A total of 56 patients (38.9%) 
successfully completed the 6 cycles of study therapy, ac-
cording to the study protocol’s requirements. The most 
common reasons for premature study therapy discon-
tinuation were disease progression (n=55), patient’s 
decision (n=14), physician’s decision (n=7), and less to 
follow-up (n=5).
A total of 46 (31.9%) patients received at least one 
dose of additional anticancer therapy after study ther-
apy discontinuation, which was predominantly chemo-
therapy (36/46, 78.3%) and/or hormonal, biological or 
immunotherapy (23/46, 50.0%).
In the tumor response population, 5 patients (3.8%) 
had a CR as their best clinical response and 39 patients 
(29.5%) had a PR, resulting in an overall response rate 
of 33.3%. An additional 60 patients (45.5%) had stable 
disease (SD) as their best response and, therefore, the 
disease control rate was 78.8%. The median duration of 
response for the 44 responding patients was 5.8 months 
(95% CI: 4.5-12.4 months).
The median TTP was 5.1 months (95% CI: 4.2-6.2 
months). The Kaplan-Meier (KM) curve for TTP is 




 range (minimum-maximum) 26-67
Karnofsky performance status 
 Median score 90
 >70% to ≤ 80% 55 (38.2)
 >80% to ≤ 100% 89 (61.8)
Menopausal status
 Post-menopausal 98 (68.1)
 Pre-menopausal 46 (31.9)
Estrogen receptor (ER) status
 er negative 41 (28.5)
 er positive 60 (41.7)
 unknown 43 (29.9)
Progesterone receptor (PR) status
 Pr negative 46 (31.9)
 Pr positive 49 (34.0)
 unknown 49 (34.0)
Pathological diagnosis
 ductal breast carcinoma 131 (91.0)
 lobular breast carcinoma 8 (5.6)
 Medullary breast carcinoma 1 (0.7)
 Others 4 (2.8)
Time since initial diagnosis, years
 Median 2.3
 range (minimum-maximum) 0.3-12.9
Disease stage at study entry
 locally advanced 1 (0.7)
 Metastatic 143 (99.3)
Previous treatment
 Surgery 132 (91.7)
 adjuvant chemotherapy 120 (83.3)
 adjuvant hormonal therapy or     
   immunotherapy 72 (50.0)
 radiotherapy 99 (68.7)
 Chemotherapy for la or MBC 60 (41.7)
 Hormonal therapy for la or MBC 34 (23.6)
Prior adjuvant chemotherapy
 Median time since treatment 
   ceased, years 1.9
 Median number of cycles given 6
Prior chemotherapy for LA or MBC
 Median time since treatment 
   ceased, years 0.3
 Minimum-maximum time since 
    treatment ceased, years 0.0-2.6
Measurable disease
 Median number of sites 2
        1 site 50 (34.7)
        2 sites 47 (32.6)
        ≥3 sites 47 (32.6)
n=number of patients with data; la=locally advanced breast cancer; MBC=metastatic 
breast cancer.
Table 1 cont. Baseline patient characteristics (n=144).
Characteristics n (%)
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shown in Figure 1. Fifty-one patients died during the 
study period, and 41 of these deaths were related to 
study disease, 1 was considered to be study drug-relat-
ed, and 9 were due to other causes. The KM estimate of 
one-year survival probability was 73.4% (95% CI: 65.1-
81.6%). Median OS was not reached. The KM curve 
for OS is shown in Figure 2. Ninety-three patients 
(64.6%) were censored in the KM analysis of OS and 
the median follow-up time for OS was 15.6 months 
(95% CI: 14.3-16.6 months).
The most common (≥10.0%) treatment-emergent 
adverse events (TEAEs) are summarized in Table 2. 
The most common (≥5.0%) grade 3 or 4 TEAEs were 
nausea/vomiting (20.1%), neutropenia (19.4%), anemia 
(13.9%), asthenic conditions (11.1%), diarrhea (9.7%), 
stomatitis and ulceration (7.6%), leucopenia (7.6%), 
and thrombocytopenia (6.2%). There were a total of 
12 serious adverse events reported, including diarrhea 
(n=3), vomiting (n=1), abdominal cramps (n=1), acute 
myocardial infarction (n=1), and cardiac arrest (n=1). 
Four patients were hospitalized during the study due 
to adverse events. Thirty patients required 98 transfu-
sions during the study (packed cell, n=74; whole blood, 
n=16; platelets, n=6; other, n=2).
DISCUSSION
Due to the frequent use of anthracycline- and taxane-
based regimens in the adjuvant and neoadjuvant set-
tings, there is a need for effective, non-cross-resistant 
chemotherapeutic agents with minimal toxicity for the 
treatment of advanced breast cancer. The combination 
of gemcitabine and cisplatin is one of the most widely 
investigated gemcitabine combinations in metastatic 
breast cancer. To our knowledge, this was the largest 
phase 2 study conducted to date to examine the effi-
cacy and safety of gemcitabine and cisplatin in women 
with unresectable, locally recurrent or metastatic breast 
cancer whose disease had progressed following prior 
treatment with one anthracycline-containing chemo-
therapy regimen (with or without taxanes). The results 
of our study showed that the study therapy was ac-
tive and generally well-tolerated. The overall response 
rate was 33.3%, which is within the range of response 
rates (26.0%-62.5%) observed in previous phase 2 tri-
als in minimally and heavily pretreated patients with 
advanced breast cancer following anthracycline and/or 
taxane failure.12,13,15-24
In our study, the median duration of response in the 
responding patients was 5.8 months and the median 
time to progression was 5.1 months. These time-to-
event measures were not reported for most of the previ-
ous phase 2 trials, but the median duration of response 
ranged from 5.3 to 10.6 months in 4 of the previous 
studies12,19,22,24 and median TTP ranged from 5.2 to 
11.2 months in 5 previous studies.19-23 In our study, 
the median TTP was relatively short, but most of the 
patients (99%) had metastatic disease and 33% of the 
patients had ≥3 sites of measurable disease. The vari-
ability in the reported efficacy outcomes following com-
bination treatment with gemcitabine and cisplatin is at 
least partly due to differences in the drug doses, che-
motherapy schedules, and the number of patients and 
their characteristics. The methodology used to calculate 
time-to-progression and duration of response (i.e. cen-
soring methods) has not been reported for the majority 
of previous studies and may also account for some of the 
observed variability. 
In this study, the 1-year survival probability was 
73.4%, which is similar to that reported for one previ-
ous phase 2 study (71.4%) in patients with metastatic 
or refractory breast cancer who were pretreated with 
1 or 2 previous chemotherapy regimens including an-
thracycline or taxane combinations.21 Median OS was 
not reached in our study but ranged from 13.5 to 27.9 
months in two previous trials with 16 to 38 patients 
with refractory or metastatic breast cancer pretreated 
with anthracycline- or taxane-containing chemotherapy 
regimens.21,23 Both of these previous studies used lower 
doses of gemcitabine and cisplatin than were used in 
our study. 
Table 2. Summary of the most common treatment-emergent adverse events (≥10.0% 
overall). 
Adverse event Grade 1 or 2n (%)




nausea/vomiting 56 (38.9) 29 (20.1) 85 (59.0)
anemia 33 (22.9) 20 (13.9) 53 (36.8)
neutropenia 24 (16.7) 28 (19.4) 52 (36.1)
leucopenia 28 (19.4) 11 (7.6) 39 (27.1)
asthenic conditions 22 (15.3) 16 (11.1) 38 (26.4)
appetite disorder 29 (20.1) 5 (3.5) 34 (23.6)
diarrheaa 20 (13.9) 14 (9.7) 34 (23.6)
Stomatitis and ulceration 14 (9.7) 11 (7.6) 25 (17.4)
gastritisa 23 (16.0) 0 (0.0) 23 (16.0)
Bone-related signs and 
symptoms 18 (12.5) 1 (0.7) 19 (13.2)
Thrombocytopenia 9 (6.2) 9 (6.2) 18 (12.5)
alopecia 16 (11.1) 0 (0.0) 16 (11.1)
values based on  World Health Organization (WHO) severity criteria.
aexcluding infective diarrhea or gastritis.
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Figure 1. Kaplan-Meier distribution of time-to-disease progression. Figure 2. Kaplan-Meier distribution of overall survival time.
Consistent with results from previous phase 2 
studies in patients pretreated with anthracyclines 
and/or taxanes, the most prevalent grade 3 or 4 toxici-
ties observed in our study were neutropenia (19.4%), 
anemia (13.9%), leucopenia (7.6%), nausea/vomiting 
(20.1%), and asthenic conditions (11.1%).12,13.15-19,21-
24 However, most toxicities were mild to moderate 
(grade 1 or 2) and, overall, toxicity was generally man-
ageable. 
A limitation of our study design was the absence of 
human epidermal growth factor receptor-2 (HER2) 
testing. When the study was designed, the importance 
of the triple negative subset of metastatic breast cancer 
was not yet evident and HER2 testing was not rou-
tinely available at all of the participating investigative 
sites. Therefore, we have not been able to report the 
outcomes for patients with triple negative or HER2-
positive disease. Nonetheless, the results of this study 
are consistent with those from previous phase 2 tri-
als and indicate that the combination of gemcitabine 
and cisplatin was active and had an acceptable toxicity 
profile in anthracycline- and/or taxane-pretreated pa-
tients with advanced breast cancer. Further research is 
required to investigate the efficacy and safety of this 
combination regimen in patients with earlier stage dis-
ease or triple negative disease.
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